News
VNRX
0.7430
-0.91%
-0.0068
Cantor Fitzgerald Reiterates Overweight on VolitionRX, Maintains $2.5 Price Target
Benzinga · 1d ago
VolitionRX Is Maintained at Buy by EF Hutton
Dow Jones · 1d ago
VolitionRX Price Target Maintained With a $4.50/Share by EF Hutton
Dow Jones · 1d ago
EF Hutton Maintains Buy on VolitionRX, Maintains $4.5 Price Target
Benzinga · 1d ago
Benchmark Co. Sticks to Its Hold Rating for VolitionRX (VNRX)
TipRanks · 1d ago
Tuesday Sector Leaders: Grocery & Drug Stores, Diagnostics
NASDAQ · 1d ago
VolitionRX reports FY results
Seeking Alpha · 2d ago
VNRX Stock Earnings: VolitionRX Meets EPS, Misses Revenue for Q4 2023
VolitionRX reported earnings per share of -11 cents for the fourth quarter of 2023. The company reported revenue of $243,973. This was 45.78% worse than the analyst estimate of $450,000. VolitionRx also reported results for the third quarter of 2018.
Investorplace · 2d ago
VolitionRX Q4 EPS $(0.11), Inline, Sales $243.97K Miss $450.00K Estimate
VolitionRX reports quarterly losses of $0.11 per share which met the analyst consensus estimate. Company reported quarterly sales of $243.97 thousand which missed the analyst estimate of $450.00 thousand by 45.78%. The company reported a 15.38 percent increase in sales from the same period last year.
Benzinga · 2d ago
VolitionRx Cash And Cash Equivalents As Of December 31, 2023, Totaled ~$20.7M
Recorded approximately $775,000 in revenue in 2023, up 153% over the prior year. Cash and cash equivalents as of December 31, 2023 totaled approximately $20.7 million. Received $13.0 million in milestone payments from Heska Corporation in December 2023. Volition will hold a conference call on March 26, 2024 to discuss the fourth quarter and full year of 2023 and upcoming milestones.
Benzinga · 2d ago
Weekly Report: what happened at VNRX last week (0318-0322)?
Weekly Report · 3d ago
Earnings Scheduled For March 25, 2024
Bitcoin Depot is expected to report quarterly loss at $0.08 per share on revenue of $161.50 million. Syra Health is likely to report earnings for its fourth quarter. Other companies reporting before the bell and after the bell include BuzzFeed and Rekor Systems.
Benzinga · 3d ago
Notable earnings after Monday's close
Major earnings expected after the bell on Monday include: AP, WPRT, FLNT, VNRX, DADA, BKKT, TMC. Other major earnings slated for release after Monday's close include: Dada Nexus Limited and Westport Fuel Systems.
Seeking Alpha · 3d ago
Earnings Outlook For VolitionRX
VolitionRX is set to give its latest quarterly earnings report on Monday, 2024-03-25. Analysts estimate the company will report an earnings per share of $-0.11. Last quarter the company beat EPS by $0.02. Shares of VolitionRx are down 56.57% over the last 52-week period.
Benzinga · 6d ago
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time to discuss its financial and operating results for the fourth quarter and full year 2023. Volition will also provide a business update. A live audio webcast of the conference call will be available on Volition's website.
PR Newswire · 03/21 12:30
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
Volition has agreed a supply agreement with Fujifilm Vet Systems Co. Ltd to launch the Nu.Q® Vet Cancer Test to veterinarians in Japan. The test is an accessible and affordable screening tool for dogs to aid in early cancer detection. Volition is a multi-national epigenetics company.
PR Newswire · 03/20 12:30
Volition appoints new medical chief
Multi-national epigenetics company, VolitionRx appointed Dr Andrew Retter as its chief medical officer, effective April 1, 2024. Retter is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust in London. Healthcare Volition appoints new medical chief.
Seeking Alpha · 03/20 07:19
VolitionRx Names Andrew Retter Chief Medical Officer
NASDAQ · 03/20 02:01
Weekly Report: what happened at VNRX last week (0311-0315)?
Weekly Report · 03/18 12:02
Weekly Report: what happened at VNRX last week (0304-0308)?
Weekly Report · 03/11 11:58
More
Webull provides a variety of real-time VNRX stock news. You can receive the latest news about Volitionrx through multiple platforms. This information may help you make smarter investment decisions.
About VNRX
VolitionRx Limited is a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop blood tests to help diagnose and monitor a range of diseases, including certain cancers and diseases associated with NETosis, such as sepsis and COVID-19. The Company’s tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluids. Its Nucleosomics technology uses chromosomal structures called nucleosomes as biomarkers in cancer and other diseases. Its key pillars include Nu.Q Cancer , Nu.Q NETs, Nu.Q Capture, Nu.Q Discover and Nu.Q Vet. Its Nu.Q family of tests acts as an early warning system by monitoring treatment response, disease progression and remission. Its Nu.Q tests use epigenetic information from tumor cells nucleosomes that helps physicians select the treatment for each patient, monitor their response and disease progression.